Safety and efficacy of osimertinib 160 mg daily given concurrently with a strong CYP3A4 inducer
Our case illustrates that 160 mg of osimertinib administered concurrently with a strong CYP3A4 inducer can be given safely and with retained efficacy in treating CNS metastatic EGFR-positive non-small cell lung cancer.
Authors
- Paul J. Hesketh (ORCID: https://orcid.org/0000-0003-3099-5427)
- Andrew J. Piper-Valillo (ORCID: https://orcid.org/0000-0003-0742-0350)
- Joel Oster (ORCID: https://orcid.org/0000-0002-1895-4326)
- Mostafa Aglan (ORCID: https://orcid.org/0000-0002-5849-1223)
- Erin Spyropoulous
Institutions
- Lahey Hospital and Medical Center (US)
- Tufts Medical Center (US)
- Lahey Medical Center (US)
Publication Details
- Journal
- Respiratory Medicine Case Reports
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.rmcr.2025.102200
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00